- Home
- INTU vs AZN Comparison
INTU vs AZN Comparison
Compare INTU & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTU | AZN |
|---|---|---|
| Founded | 1983 | 1992 |
| Country | United States | United Kingdom |
| Employees | 18200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.1B | 276.3B |
| IPO Year | 1993 | 1993 |
Fundamental Metrics
Financial Performance| Metric | INTU | AZN |
|---|---|---|
| Price | $669.79 | $89.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 2 |
| Target Price | ★ $811.72 | N/A |
| AVG Volume (30 Days) | 2.0M | ★ 5.6M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | 0.72% | ★ 1.71% |
| EPS Growth | 41.77 | ★ 45.02 |
| EPS | ★ 14.57 | 6.02 |
| Revenue | $19,433,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $14.85 | $11.33 |
| Revenue Next Year | $12.47 | $6.08 |
| P/E Ratio | $46.03 | ★ $14.93 |
| Revenue Growth | ★ 17.14 | 13.52 |
| 52 Week Low | $532.65 | $61.24 |
| 52 Week High | $813.70 | $94.02 |
Technical Indicators
Market Signals| Indicator | INTU | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 52.24 |
| Support Level | $650.47 | $89.70 |
| Resistance Level | $676.60 | $91.66 |
| Average True Range (ATR) | 16.56 | 1.30 |
| MACD | 3.68 | -0.41 |
| Stochastic Oscillator | 82.54 | 8.55 |
Price Performance
Historical ComparisonAbout INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small-to-midsize business accounting and self-serve tax filing in the US.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.